EMMAC Life Sciences Group Appoints Lorne Abony as Chairman of the Board

19 November 2019, London. EMMAC Life Sciences Group, Europe’s leading independent cannabis company is pleased to announce that it has appointed Lorne Abony as Chairman of the Board of Directors. Mr. Abony, a well-known entrepreneur, is the former CEO of Nuuvera Corp., a Canadian cannabis company that listed on the Toronto Stock Exchange and was acquired by Aphria in March 2018.  Mr. Abony is also Chairman of Socati Corp, which produces broad-spectrum hemp extract, and is CEO of FastForward Innovations Limited, an AIM-listed investment company that is focused on life sciences and emerging technologies.  Previously, Mr. Abony was the CEO of Mood Media Corporation, a large publicly traded media entity employing 3,300 people in 47 countries. In 2001, Mr. Abony co-founded FUN Technologies, a Canadian online gaming company which was acquired by Liberty Media in December 2007.

Lorne Abony, Chairman of EMMAC, commented: “I am excited to be joining EMMAC as Chairman during this important phase of its growth. I look forward to working closely with our experienced management and research teams to firmly establish EMMAC as Europe’s leading cannabis company.”

Antonio Costanzo, CEO of EMMAC, added: “We are thrilled to welcome Lorne as EMMAC’s Chairman. With the our recent £15 million fundraise complete, we believe that now is the right time to bring in someone with Lorne’s experience and proven track record of creating high value organisations both within and outside the medical cannabis sector. His guidance and advice will be invaluable as EMMAC scales its operations across Europe.”


EMMAC Life Sciences Group is Europe’s leading independent cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, EMMAC’s vision is to bring the life-enhancing potential of cannabis to the people who need it.


For scientific enquiries please contact research@emmac.com

For general enquiries please contact info@emmac.com or visit www.emmac.com

Media enquiries:

Henry Harrison-Topham / Jamie Hooper / Ariadna Peretz Tel: +44 (0) 20 7466 5000
emmac@buchanan.uk.com www.buchanan.uk.com


All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences Group. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.

Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. EMMAC Life Sciences Group assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.